Format

Send to

Choose Destination
J Clin Oncol. 2019 Jun 10;37(17):1460-1469. doi: 10.1200/JCO.18.02459. Epub 2019 Mar 20.

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.

Author information

1
1 University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium.
2
2 Netherlands Cancer Institute, Amsterdam, the Netherlands.
3
3 West Cancer Center, Germantown, TN.
4
4 Memorial Sloan Kettering Cancer Center, New York, NY.
5
5 Imelda General Hospital, Bonheiden, Belgium; University Hospitals Gasthuisberg, Leuven, Belgium.
6
6 Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain.
7
7 City of Hope Comprehensive Cancer Center, Duarte, CA.
8
8 Hospital del Mar-Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra, Barcelona, Spain.
9
9 Antwerp University Hospital, Edegem, Belgium.
10
10 National Cancer Center Hospital East, Kashiwa, Japan.
11
11 Hammersmith Hospital, Imperial College London, London, United Kingdom.
12
12 Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
13
13 University of Campania "Luigi Vanvitelli," Naples, Italy.
14
14 Array BioPharma Inc, Boulder, CO.
15
15 Utrecht University, Utrecht, the Netherlands.
16
16 The University of Texas MD Anderson Cancer Center, Houston, TX.

Abstract

PURPOSE:

To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, three-arm, phase III BEACON Colorectal Cancer trial ( ClinicalTrials.gov identifier: NCT02928224; European Union Clinical Trials Register identifier: EudraCT2015-005805-35).

PATIENTS AND METHODS:

Before initiation of the randomized portion of the BEACON Colorectal Cancer trial, 30 patients with BRAF V600E-mutant mCRC who had experienced treatment failure with one or two prior regimens were to be recruited to a safety lead-in of encorafenib 300 mg daily, binimetinib 45 mg twice daily, plus standard weekly cetuximab. The primary end point was safety, including the incidence of dose-limiting toxicities. Efficacy end points included overall response rate, progression-free survival, and overall survival.

RESULTS:

Among the 30 treated patients, dose-limiting toxicities occurred in five patients and included serous retinopathy (n = 2), reversible decreased left ventricular ejection fraction (n = 1), and cetuximab-related infusion reactions (n = 2). The most common grade 3 or 4 adverse events were fatigue (13%), anemia (10%), increased creatine phosphokinase (10%), increased AST (10%), and urinary tract infections (10%). In 29 patients with BRAF V600E-mutant tumors (one patient had a non-BRAF V600E-mutant tumor and was not included in the efficacy analysis), the confirmed overall response rate was 48% (95% CI, 29.4% to 67.5%), median progression-free survival was 8.0 months (95% CI, 5.6 to 9.3 months), and median overall survival was 15.3 months (95% CI, 9.6 months to not reached), with median duration of follow-up of 18.2 months (range, 16.6 to 19.8 months).

CONCLUSION:

In the safety lead-in, the safety and tolerability of the encorafenib, binimetinib, and cetuximab regimen is manageable and acceptable for initiation of the randomized portion of the study. The observed efficacy is promising compared with available therapies and, if confirmed in the randomized portion of the trial, could establish this regimen as a new standard of care for previously treated BRAF V600E-mutant mCRC.

PMID:
30892987
DOI:
10.1200/JCO.18.02459

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center